[Objective evaluation of immunosuppressive therapy in progressive polyarthritis using Imuran and Leukeran].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Hándlová.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effects of Benetazone Spofa (trimethazone) in a dose of 1000 mg/day with those of phenylbutazone in a dose of 600 mg day in patients with rheumatoid arthritis were tested in a short-term double-blind trial (3 weeks) and in a long-term double-blind trial (12 weeks). The short-term trial failed to disclose a significant superior effect of phenylbutazone, and the continued prolonged therapy showed, on the contrary, the higher effectiveness of the new derivative, but the difference was not statistically significant. The main advantage of Benetazone consisted of its lower toxicity, better tolerance and of the much lower tendency to produce fluid retention compared to phenylbutazone.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effects of niflumic acid (trifluoro-methyl-3-phenylamino-2-nicotinic acid) and of aloxiprin (aluminium acetyl-salicylate) in patients with rheumatoid arthritis were compared in a double-blind cross-over trial. Check-up examinations prior to the institution and after the termination of the therapy, as well as after individual treatment periods of two weeks with alternating sequential administration of the two drugs, were carried out with a standardized method. The assessment included subjective (pain intensity) and objective criteria (Lansbury's index), as well as laboratory results (erythrocyte sedimentation rate, uricaemia). With the exception of the articular index disclosing a superior effect of niflumic acid, the other criteria showed no statistically significant differences between the effects of the two drugs.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.